Autoantibody panel for early diagnosis of colorectal cancer
The invention offers an autoantibody set that can be used as a diagnostic tool for diagnosis and stratification of colorectal cancer patients.
Sigmoidoscopy and colonoscopy, the current gold standards for detection of CRC in the distal and total colorectum, respectively, are limited by several disadvantages, such as high costs, limited resources and poor compliance. So other cost-effective and sensitive methods for the early detection of colorectal cancer are urgently needed and very important from the health economic standpoint. Using blood samples the invention offers an autoantibody set that can be used as a diagnostic tool for diagnosis and stratification of colorectal cancer.
Using biological (blood) samples from a screening colonoscopy study including approx. 6800 participants a core panel of 4 proteins was identified without substantial loss of predictive power. Sensitivity of this core marker set was 26% (95% CI, 13−45%) for early stage CRC at a specificity of 90% (95% CI, 83−94%).
High costs, limited resources and poor compliance of the standard ways of detection of CRC in the distal and total colorectum.
Using biological (blood) samples from a screening colonoscopy study
- Autoantibody marker panel for diagnosis and stratification of colorectal cancer.
- Based on a cohort of screening colonoscopy participants of the BliTz study between 2005-2013, including approx. 6,800 participants.
- High sensitivity i.e. 90% for early stage CRC.
DKFZ is looking for a commercial partner for further development of the marker panel alone or in combination with other markers towards clinical application.
Publikationen & Verweise
“Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting.” By Chen H, Werner S, Butt J, Zörnig I, Knebel P, Michel A, Eichmüller SB, Jäger D, Waterboer T, Pawlita M, Brenner H. published in Oncotarget. 2016 Feb 19. See at: https://www.ncbi.nlm.nih.gov/pubmed/?term=26909861 .doi: 10.18632/oncotarget.7500.
Weitere Information zum Herunterladen
- 213 Ki